Should I buy or sell BioGaia AB (publ) stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioGaia AB (publ) in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOGY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOGY, but not buy additional shares or sell existing shares. View BIOGY analyst ratings or view top-rated stocks .

How have BIOGY shares performed in 2023?

BioGaia AB (publ)'s stock was trading at $8.50 on January 1st, 2023. Since then, BIOGY stock has increased by 17.6% and is now trading at $10.00. View the best growth stocks for 2023 here .

How often does BioGaia AB (publ) pay dividends? What is the dividend yield for BioGaia AB (publ)?

BioGaia AB (publ) declared a dividend on Wednesday, May 3rd. Investors of record on Tuesday, May 9th will be paid a dividend of $0.1996 per share on Tuesday, May 30th. This represents a yield of 2.26%. The ex-dividend date is Monday, May 8th. Read our dividend analysis for BIOGY .

When did BioGaia AB (publ)'s stock split?

BioGaia AB (publ) shares split on Thursday, May 26th 2022. The 2.5-1 split was announced on Thursday, May 26th 2022. The newly issued shares were distributed to shareholders after the market closes on Thursday, May 26th 2022. An investor that had 100 shares of stock prior to the split would have 250 shares after the split.

How do I buy shares of BioGaia AB (publ)?

Shares of BIOGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

BioGaia AB (publ) Stock Price, News & Analysis (OTCMKTS:BIOGY)

$10.00

0.00 (0.00%)

(As of 12/5/2023 ET)

Compare

Today's Range: $10.00
▼
$10.00
50-Day Range: $8.84
▼
$10.00
52-Week Range: $8.36
▼
$10.00

Volume: N/A
Average Volume: 460 shs
Market Capitalization: N/A

P/E Ratio: 2.38
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Dividend Financials Headlines SEC Filings Short Interest

About BioGaia AB (publ) Stock (OTCMKTS:BIOGY)

BioGaia AB (publ), a healthcare company, develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula. The Adult Health segment provides gut health tablets and oral health lozenges products, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. The company offers its products in the areas of infantile colic; antibiotic-associated and acute diarrhoea; gingivitis; periodontal disease; Helicobacter pylorithe gastric ulcer bacterium; low bone density; and diverticulitis, as well as baby and child gut, adult gut, immune, pregnancy, oral, and bone health. It offers its products under the BioGaia brand name. The company sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is headquartered in Stockholm, Sweden.

BIOGY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOGY Stock News Headlines

September 21, 2023 | uk.investing.com

BioGaia AB ser. B (0GTN)

September 13, 2023 | wsj.com

BioGaia AB Series B

December 6, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

August 1, 2022 | apnews.com

Changed Number of Shares and Votes in IRLAB Therapeutics AB

See More Headlines

Receive BIOGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioGaia AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BIOGY
CUSIP: N/A
CIK: 1572957
Web: www.biogaia.com
Phone: (685) 552-9300
Fax: N/A
Employees: 213
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 2.38
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Peter Rothschild M.Sc. Econ. (Age 73)
MBA, Founder & Chairman
Comp: $1.3M
Mr. Alexander Kotsinas M.Sc. (Eng.). (Age 56)
Executive VP & CFO
Comp: $2.98M
Ms. Theresa P. Agnew
CEO & President
Ludvig Milesson (Age 46)
Chief Operating Officer
Mr. Gianfranco Grompone (Age 48)
Chief Scientific Officer and VP of Research & Development
Ms. Caroline Mofors (Age 51)
Chief Legal Officer
Ms. Linda Hagglund (Age 50)
Vice President of Marketing
Ms. Angelika Kjelldorff (Age 54)
Chief HR Officer
Sebastian Heimfors (Age 49)
VP & Chief Commercial Officer
Jonathan Gromark
Sustainability Manager

Key Competitors

View All Competitors

BIOGY Stock Analysis - Frequently Asked Questions

Should I buy or sell BioGaia AB (publ) stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioGaia AB (publ) in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOGY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOGY, but not buy additional shares or sell existing shares.
View BIOGY analyst ratings or view top-rated stocks.
How have BIOGY shares performed in 2023?: BioGaia AB (publ)'s stock was trading at $8.50 on January 1st, 2023. Since then, BIOGY stock has increased by 17.6% and is now trading at $10.00.
View the best growth stocks for 2023 here.
How often does BioGaia AB (publ) pay dividends? What is the dividend yield for BioGaia AB (publ)?: BioGaia AB (publ) declared a dividend on Wednesday, May 3rd. Investors of record on Tuesday, May 9th will be paid a dividend of $0.1996 per share on Tuesday, May 30th. This represents a yield of 2.26%. The ex-dividend date is Monday, May 8th.
Read our dividend analysis for BIOGY.

When did BioGaia AB (publ)'s stock split?: BioGaia AB (publ) shares split on Thursday, May 26th 2022. The 2.5-1 split was announced on Thursday, May 26th 2022. The newly issued shares were distributed to shareholders after the market closes on Thursday, May 26th 2022. An investor that had 100 shares of stock prior to the split would have 250 shares after the split.
How do I buy shares of BioGaia AB (publ)?: Shares of BIOGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BIOGY) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial